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Acute generalized exanthematous pustulosis
(AGEP) is usually a drug-related severe reaction
characterized by an acute rash with pinhead-sized
sterile pustules on erythematous ground, often start-
ing in the main folds.1 Systemic involvement can
occur in approximately 20% of cases of AGEP and
themortality rate is less than 5%. Although symptoms
resolve within 15 days in most cases, prolonged
courses have been reported.2
Drug-induced AGEP is considered a T-celle
mediated reaction with concomitant activation
of neutrophils.3 Increasing evidence indicates
that interleukin (IL) 17 is an important factor
in the pathogenesis of AGEP in concert with
other proinflammatory mediators. Increased IL-
17 levels have also been found in patients with
AGEP.4 Here, we report a case of recalcitrant
AGEP elicited by hydroxychloroquine, with
rapid clinical improvement after a single treat-
ment with the antieIL-17 monoclonal antibody
ixekizumab.CASE REPORT
A 76-year-old man presented to our outpatient
clinic with an acute rash that started 18 days after
intake of hydroxychloroquine (400 mg/d) for the
treatment of calcium pyrophosphate dihydrate crys-
tal deposition disease. Intake of other concomitant
medication or symptoms of infection were denied.
Neither the patient nor members of his family had a
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generalized erythematous rash with widespread
nonfollicular, pinpoint pustules, mainly on the trunk
and in the axillary folds (Fig 1, A and B). There was
no mucosal involvement. Bacteriologic examination
result for a pustule was negative. Laboratory tests
showed elevated levels of C-reactive protein (44 mg/
L; normal \3 mg/L) and leukocytosis (12 G/L;
normal range 3.0-10.5 G/L), as well as neutrophilia
(10.46 G/L; normal range 1.6-7.4 G/L). His serum
creatinine level was elevated (122 mol/L; normal
range 59-104 mol/L) and creatinine clearance was
low (52 mL/min; normal 59 mL/min) because of
preexisting chronic kidney disease. Liver enzyme
levels were normal.
Histopathologic examination showed diffuse
spongiosis of the epidermis and formation of sub-
corneal pustules. Mild lichenoid inflammation was
observed at the dermoepidermal junction and a
perivascular infiltrate with lymphocytes and histio-
cytes, along with conspicuous neutrophils and
eosinophils, was present in the superficial dermis
(Fig 2, A). Immunohistologic staining for IL-17A was
performed as described previously5 and showed
increased IL-17A expression in the inflammatory
infiltrate and the pustule (Fig 2, B). The AGEPJAAD Case Reports 2020;6:634-6.
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Fig 1. Clinical presentation before (A and B) and after (C) a single treatment with ixekizumab
160 mg subcutaneously.
Fig 2. A, Staining of a pustule. B, Immunoreactivity for interleukin 17A in the inflammatory
infiltrate and the pustule. (A and B, Hematoxylin-eosin stain; original magnification 310.)
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Adverse Reactions study group6 was 10, indicating
AGEP.
Despite the discontinuation of hydroxychloro-
quine and treatment with topical steroids (clobetasol
propionate 0.05% ointment andmometasone furoate
0.1% cream) and systemic steroids (50-80 mg/d), the
rash worsened and levels of inflammatory parame-
ters in the peripheral blood increased (leukocytosis
22.7 G/L; C-reactive protein 74 mg/L). Because of the
recalcitrant course of the disease for 4 weeks,
therapy with ixekizumab 160 mg subcutaneously
(single dose) was initiated. Within 5 days, a marked
improvement of the skin and decreased inflamma-
tory parameters (leukocytosis 7.92 G/L, neutrophils
6.4 G/L, and C-reactive protein 33 mg/L) were noted,
and after 11 days, only slight erythemawas visible. In
the follow-up visits after 1, 2, 6, 12, and 21 months,
no new flare-up was observed (Fig 1, C).DISCUSSION
AGEP is a rare but potentially life-threatening
reaction, mainly caused by drugs. The agents
commonly implicated in the development of AGEP
include aminopenicillins, quinolines, macrolides,
sulfonamides, terbinafine, diltiazem, and, as in our
case, antimalarials. Although the symptoms of AGEP
typically resolve within 15 days after the discontin-
uation of the causative drug, a prolonged disease
course with several flares, particularly after hydroxy-
chloroquine use, has been reported.2 A prolonged
disease course extending beyond 15 days could be
due to the long half-life of hydroxychloroquine,
which is approximately 45 days. Because hydroxy-
chloroquine is mainly excreted by the kidneys, renal
impairment with a subsequently lower clearance of
the drug may also have contributed to the continual
symptoms in our patient. Rarely, antimalarial drugs
have been reported to induce or exacerbate pustular
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can be challenging.7 Together with the high AGEP
validation score of the European Severe Cutaneous
Adverse Reactions study group, the absence of a
personal or family history of psoriasis and psoriasis
arthritis, the lack of recurrence of pustular lesions at
follow-up, and some histologic findings such as the
presence of eosinophils and slight lichenoid inflam-
mation support our diagnosis of AGEP.
To date, the pathophysiology of AGEP and the
mechanism of neutrophilic skin inflammation are not
fully elucidated. Initially, CD41 and CD81 T cells as
well as cytotoxic mediators including granzyme B/
perforin and Fas ligand were thought to play major
roles in eliciting neutrophilic skin inflammation.1,3
After keratinocyte activation, partly with apoptosis
and vesicle formation, increased amounts of proin-
flammatory cytokines (eg, tumor necrosis factor-a,
IL-36) and chemokines (in particular CXCL-8) are
released, leading to chemotaxis and neutrophil
activation with subsequent pustule formation.
Furthermore, T-helper type 17 effector cytokines,
namely, IL-17 and IL-22, may synergistically partic-
ipate in stimulating keratinocytes to produce IL-8.5 It
has also been suggested that besides T-helper
17 cells, innate immune cells such as neutrophils,
mast cells, andmacrophages are a source of IL-17A in
AGEP.5 This is in accordance with the findings of our
immunohistochemical analyses, which showed
increased IL-17 expression in the inflammatory
infiltrate and the pustule (Fig 2, B).
Ixekizumab is a high-affinity, humanized, antieIL-
17A, monoclonal antibody that has been approved
for treating severe plaque psoriasis and psoriasis
arthritis.8 It has also been approved for treating
pustular and erythrodermic psoriasis in Japan.9
Ixekizumab acts faster and is more efficacious
compared with other biologics such as etanercept
and ustekinumab.8 The rationale for treating our
patient with ixekizumab was as follows: First, the
patient had a severe and prolonged disease course
and was unresponsive to topical and systemic corti-
costeroids. Second, IL-17 could potentially have been
involved in the pathogenesis of AGEP together with
IL-17 upregulation in the skin lesion of our patient.
Third, there is evidence for the positive therapeuticeffect of ixekizumab on generalized pustular psoria-
sis, which is also related to neutrophilic skin inflam-
mation. Fourth, severe AGEP has been successfully
treated previously in 2 patients with secukinumab,
another antieIL-17 antagonist.10,11
In conclusion, physicians should be aware that
hydroxychloroquine may induce an atypical and
prolonged course of AGEP, and IL-17 inhibitors
such as ixekizumab can help treat prolonged,
recalcitrant AGEP.
We thank Ursula L€aderach for her excellent technical
assistance.
REFERENCES
1. Szatkowski J, Schwartz RA. Acute generalized exanthematous
pustulosis (AGEP): a review and update. J Am Acad Dermatol.
2015;73(5):843-848.
2. Pearson KC, Morrell DS, Runge SR, Jolly P. Prolonged pustular
eruption from hydroxychloroquine: an unusual case of acute
generalized exanthematous pustulosis. Cutis. 2016;97(3):
212-216.
3. Feldmeyer L, Heidemeyer K, Yawalkar N. Acute generalized
exanthematous pustulosis: pathogenesis, genetic background,
clinical variants and therapy. Int J Mol Sci. 2016;17(8):1214.
4. Kabashima R, Sugita K, Sawada Y, Hino R, Nakamura M,
Tokura Y. Increased circulating Th17 frequencies and serum
IL-22 levels in patients with acute generalized exanthematous
pustulosis. J Eur Acad Dermatol Venereol. 2011;25(4):485-488.
5. Kakeda M, Schlapbach C, Danelon G, et al. Innate immune cells
express IL-17A/F in acute generalized exanthematous pustu-
losis and generalized pustular psoriasis. Arch Dermatol Res.
2014;306(10):933-938.
6. Sidoroff A, Halevy S, Bavinck JN, Vaillant L, Roujeau JC. Acute
generalized exanthematous pustulosis (AGEP)-a clinical reac-
tion pattern. J Cutan Pathol. 2001;28(3):113-119.
7. Friedman SJ. Pustular psoriasis associated with hydroxychlor-
oquine. J Am Acad Dermatol. 1987;16(6):1256-1257.
8. Syed YY. Ixekizumab: a review in moderate to severe plaque
psoriasis. Am J Clin Dermatol. 2017;18(1):147-158.
9. Okubo Y, Mabuchi T, Iwatsuki K, et al. Long-term efficacy and
safety of ixekizumab in Japanese patients with erythrodermic
or generalized pustular psoriasis: subgroup analyses of an
open-label, phase 3 study (UNCOVER-J). J Eur Acad Dermatol
Venereol. 2019;33(2):325-332.
10. Gualtieri B, Solimani F, Hertl M, Buhl T, M€obs C, Pf€utzner W.
Interleukin 17 as a therapeutic target of acute generalized
exanthematous pustulosis (AGEP). J Allergy Clin Immunol Pract.
2020;8(6):2081-2084.e2.
11. Gualtieri B, M€obs C, Solimani F, Hertl M, Pf€utzner W. Wirksam-
keit des IL-17-Hemmers SECUKINUMAB bei akuter general-
isierter exanthematische Pustulose (AGEP). J Dtsch Dermatol
Ges. 2019;17(suppl 2):22-24.
